PCSK9 is the most established one, since it has been known for more than a decade that gain‐of‐function and loss‐of‐function variants in the PCSK9 gene increase (Abifadel et al, 2003) and decrease (Cohen et al, 2006) the risk of CAD and MI, respectively. This evidence concerns the gene PCSK9 and coronary artery disorder.